N-(2-methoxyethyl)-2-methylbutanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(2-methoxyethyl)-2-methylbutanamide
• 化学式: C₈H₁₇NO₂
• 分子量: 159.23
• InChiKey: QHUGSAOWTLJLAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Edmondson Scott D.

  公开号：US20120157432A1

  公开（公告）日：2012-06-21

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供公式（I）的化合物、其制药组合物以及使用该化合物治疗或预防通过激活β3-肾上腺素受体介导的疾病的方法。
• AQUEOUS INK COMPOSITION, INK SET, AND IMAGE FORMING METHOD
  申请人：Fujifilm Corporation

  公开号：EP3770225A1

  公开（公告）日：2021-01-27

  An aqueous ink composition including: an aqueous medium and resin fine particles, in which a proportion of a high-boiling solvent occupied in the aqueous medium is 3% by mass or less, and a resin constituting the resin fine particle contains constitutional units represented by General Formula (1) or (2). In the formulae, R1 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, A1 represents -O-, -NH-, or -N(L2-Y2)-, and L1 and L2 each are represent a specific divalent group such as an alkylene group or the like. Y1 and Y2 each represent -OH, -OR2, -NH2, -NR2H, -NR2R3, -SH, -S(=O)2OM, or -OP(=O)(OM)2. R2 and R3 each represent a specific substituent, and M represents a hydrogen atom, an alkali metal ion, or an ammonium ion.

  一种水性油墨组合物，包括：水性介质和树脂微粒，其中高沸点溶剂在水性介质中所占的比例为 3% 或更少（按质量计），构成树脂微粒的树脂含有通式（1）或（2）所代表的构型单元。 式中，R1 代表氢原子或具有 1 至 4 个碳原子的烷基，A1 代表-O-、-NH-或-N(L2-Y2)-，L1 和 L2 分别代表特定的二价基团，如亚烷基等。 Y1 和 Y2 各自代表-OH、-OR2、-NH2、-NR2H、-NR2R3、-SH、-S(=O)2OM 或-OP(=O)(OM)2。R2 和 R3 分别代表一个特定的取代基，M 代表氢原子、碱金属离子或铵离子。
• KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：US20210094950A1

  公开（公告）日：2021-04-01

  Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
• US8354403B2
  申请人：——

  公开号：US8354403B2

  公开（公告）日：2013-01-15